Overview

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema

Status:
Active, not recruiting
Trial end date:
2023-08-18
Target enrollment:
Participant gender:
Summary
This is a multicenter long-term extension study designed to evaluate the long-term safety and tolerability of faricimab administered by intravitreal (IVT) injection at a personalized treatment interval (PTI) to participants who enrolled in and completed one of the two Phase III studies, GR40349 (NCT03622580) or GR40398 (NCT03622593), also referred to as the parent studies.
Phase:
Phase 3
Details
Lead Sponsor:
Hoffmann-La Roche